Skip to content
VuFind
English
Deutsch
Español
Français
Italiano
日本語
Nederlands
Português
Português (Brasil)
中文(简体)
中文(繁體)
Türkçe
עברית
Gaeilge
Cymraeg
Ελληνικά
Català
Euskara
Русский
Čeština
Suomi
Svenska
polski
Dansk
slovenščina
اللغة العربية
বাংলা
Galego
Tiếng Việt
Hrvatski
हिंदी
Հայերէն
Українська
Sámegiella
Монгол
Language
All Fields
Title
Author
Subject
Call Number
ISBN/ISSN
Tag
Find
Advanced
Economic analysis of simvastat...
Cite this
Text this
Email this
Print
Export Record
Export to RefWorks
Export to EndNoteWeb
Export to EndNote
Permanent link
Economic analysis of simvastatin in 20,536 people at different levels of vascular disease risk based on US costs: Randomised placebo-controlled trial
Bibliographic Details
Main Authors:
Mihaylova, B
,
Armitage, J
,
Briggs, A
,
Gray, A
,
Parish, S
,
Collins, R
,
Collaborati, H
Format:
Conference item
Published:
2005
Holdings
Description
Similar Items
Staff View
Similar Items
Cost-effectiveness of simvastatin in people at different levels of vascular disease risk: economic analysis of a randomised trial in 20,536 individuals.
by: Mihaylova, B, et al.
Published: (2005)
Lifetime cost effectiveness of simvastatin in a range of risk groups and age groups derived from a randomised trial of 20,536 people.
by: Mihaylova, B, et al.
Published: (2006)
Effects of simvastatin 40 mg daily on muscle and liver adverse effects in a 5-year randomized placebo-controlled trial in 20,536 high-risk people.
by: Armitage, J, et al.
Published: (2009)
N-terminal pro-B-type natriuretic peptide and vascular disease among 20,536 patients in the MRC/BHF heart protection study
by: Emberson, J, et al.
Published: (2005)
N-BNP and vascular disease among 20,536 patients in the MRC/BHF Heart Protection Study
by: Emberson, J, et al.
Published: (2005)